TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays

Thrombosis and Haemostasis

Volumn 96, Issue 2, 2006, Pages 236-237

  Schroeder, Verena ^a   Wilmer, Marianne ^b   Buehler, Beatrice ^b   Kohler, Hans Peter ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b Pentapharm Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; ARGININE CARBOXYPEPTIDASE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTITHROMBIN III DEFICIENCY; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION COEFFICIENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN DEFECT; HEMOPHILIA A; HUMAN; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN DEFICIENCY; RANK SUM TEST; RISK FACTOR; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL ASSAY; BLOOD PLATELETS; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33747087775     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-06-0295     Document Type: Letter

References (7)

1. Nesheim ME. TAFI. Review. Fibrinol Proteol 1999; 13: 72-7.
2. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
3. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
4. Gils A, Alessi MC, Brouwers E et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
5. Guimaraes AHC, van Tilburg NH, Vos HL, et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
6. Verdú J, Marco P, Berdloch S, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFl levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95: 585-6.
7. Schroeder V, Chatterjee T, Mehta H, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.